Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
GLOBETECH PUBLISHING

Molecular Assay Detects Norovirus in Fecal Specimens

By Labmedica International staff writers
Posted on 09 Jan 2014
Image: The AccuPower Norovirus Real-time RT-PCR assay kit (Photo courtesy of Bioneer Corporation).
Image: The AccuPower Norovirus Real-time RT-PCR assay kit (Photo courtesy of Bioneer Corporation).
A new real-time reverse transcription polymerase chain reaction (RT-PCR) assay has been evaluated in for the detection of human Norovirus in stool specimens.

Noroviruses are a genetically diverse group of single-stranded ribonucleic acid (RNA), nonenveloped viruses in the Caliciviridae family and are classified into five genogroups by phylogenetic analysis of the capsid protein, of which genogroups II (GII), I (GI), and IV (GIV) are responsible for human outbreak.

Scientists at the Hallym University College of Medicine (Seoul, South Korea) analyzed 281 fecal suspensions (10% to 20% fecal specimen diluted with saline) collected and stored at -70 °C between August 2010 and April 2011. These comprised 109 Norovirus-positive and 172 Norovirus-negative stool samples, as determined using a Norovirus enzyme-linked immunosorbent assay (ELISA).

RNA was extracted from fecal suspensions and prepared using the QIAamp Viral RNA Mini Kit (Qiagen; Hilden, Germany) and the Qiagen QIAcube platform. The AccuPower Norovirus Real-time RT-PCR assay (Bioneer Corporation; Daejeon, South Korea) and the RIDAGENE Norovirus V assay (R-Biopharm, Darmstadt, Germany) were compared as Norovirus assays. Norovirus positivity and genotype were confirmed by direct sequencing.

Of the 109 Norovirus-positive samples by ELISA, 91 (83.5%) were positive by both PCR kits, and two (1.8%) were positive only by the AccuPower kit, whereas 16 cases (14.7%) were negative by both PCR kits. Of the 172 Norovirus-negative samples by ELISA, 159 (92.4%) were negative, and five (2.9%) were positive by both PCR kits, one (0.6%) was positive by the RIDAGENE kit, and seven (4.1%) were positive by the AccuPower kit. The lowest mean numbers of genome copies of GI and GII that could be detected by the AccuPower assay were 12.3 and 5.6 RNA copies/reaction, respectively.

The authors concluded that the AccuPower Norovirus Real-time RT-PCR Kit showed good analytical and clinical performance, including excellent analytical sensitivity and reproducibility, without cross-reactivity and they recommend this assay system as an efficient diagnostic tool for Norovirus infection. Noroviruses are responsible for an estimated 218,000 deaths each year among children younger than five years in developing countries and 1.1 million hospitalizations worldwide. The study was published in the January 2014 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Hallym University College of Medicine
Qiagen
Bioneer Corporation 




Sekisui Diagnostics
EUROIMMUN AG
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Pathology

view channel

New Approach Identifies Multiple Melanoma Drug Resistance Biomarkers

A recent paper described the use of liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM) for assessing melanoma biomarkers in the blood in order to determine the effectiveness of chemotherapy. Modern chemotherapeutic techniques based on treatment with multiple anticancer drugs require the identification... Read more

Lab Technology

view channel
Image: Visualization from a numerical simulation of a cell flowing past the obstacle through the microfluidic device (Image courtesy of KTH – The Royal Institute of Technology).

Microfluidic Device Could Improve Biomarker Analyses

A new microfluidic device could offer a more reliable alternative for detecting biomarkers in patients facing such illnesses as cancer or malaria. The physical attributes of cells are important biomarkers... Read more

Industry News

view channel

IDT Acquires SURVEYOR Nuclease Product Line from Transgenomic

The SURVEYOR line is to be used by Integrated DNA Technologies (IDT; Coralville, IA, USA) primarily to support researchers performing mutation detection and potentially-clinical genome editing, and by Transgenomic, Inc. (Omaha, NE, USA) primarily to support diagnostic and other clinical applications. IDT, a world leader... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.